Kinpeygo (Budesonide)

Budesonide binds to intracellular glucocorticoid receptors, forming a complex that moves into the cell nucleus. There it alters gene transcription, suppressing pro‑inflammatory cytokines and chemokines while increasing anti‑inflammatory proteins, which together diminish leukocyte infiltration and edema in the gastrointestinal tract.

The dose of Kinpeygo is individualized. A prescribing physician determines the appropriate amount based on the severity of the disease, patient weight, response to therapy, and other clinical factors. No standard dosage can be provided without a specific medical prescription.

Safety data for budesonide in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Use during pregnancy or while breastfeeding should only occur if the potential benefit justifies the potential risk, and it must be decided by a qualified healthcare professional.

To order Kinpeygo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. The sales team then replies with pricing, availability, shipping details and any necessary import documentation.

Kinpeygo delivers a locally acting corticosteroid with high first‑pass metabolism, offering anti‑inflammatory effects while limiting systemic exposure compared with systemic steroids such as prednisone. It is often used when mesalamine or immunomodulators are insufficient, providing an alternative to biologic agents for patients needing targeted inflammation control.

Kinpeygo should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed when not in use.

Kinpeygo is taken orally. The tablet or capsule should be swallowed whole with water, and it may be taken with or without food according to the prescribing physician’s instructions.

The most serious risks include adrenal suppression, which can affect the body’s stress response; severe infections due to immunosuppression; and the rare possibility of a perforated gastrointestinal ulcer. Patients should be monitored closely for signs of these conditions.

Kinpeygo should be avoided in individuals with a known hypersensitivity to budesonide or any component of the formulation, in patients with uncontrolled systemic fungal infections, and in those with severe, active infections where immunosuppression could worsen the condition.